Research
We have the following ongoing clinical trials:
(If you're interested in participation or have any questions, please contact our Research Office at 313-745-9537.)
ATHENA-1 : A Randomized, Multicenter Study of Ambrisentan and Sildenafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension Who Have Demonstrated a Sub-Optimal Response to Sildenafil
Principal Investigator: Ghulam Saydain MD
COMPASS-2: Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Patients With Pulmonary Arterial Hypertension - A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Prospective, Event Driven Phase IV Study.
Principal Investigator: Ghulam Saydain MD
REVEAL Registry:Registry to Evaluate Early And Long-Term PAH Disease Management.
Principal Investigator: Ghulam Saydain MD
PAH QuERI: Pulmonary Arterial Hypertension Quality Enhancement Research Initiative.
Principal Investigator: Ghulam Saydain MD
SERAPHIN: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Event-Driven, Phase III Study to Assess the Effects of ACT-064992 on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension.
Principal Investigator: Ghulam Saydain MD
We have also successfully completed the following Clinical Trials in the past:
PHIRST-2: Open-label, Extension Study to Evaluate the Long-term Safety and Efficacy of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial Hypertension.
Principal Investigator: Ghulam Saydain MD/ Kamal Mubarak MD
ARIES-3: Phase 3, Long-Term, Open-Label, Multicenter Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension.
Principal Investigator: Ghulam Saydain MD/ Kamal Mubarak MD
STRIDE-III: Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients with Pulmonary Arterial Hypertension.
Principal Investigator: Kamal Mubarak MD
ASSET-1 & ASSET-2: Randomized, Placebo-controlled, Double-blind, Multi-center, Parallel Group Study To Assess the Efficacy, Safety and Tolerability of Bosentan in Patients with Symptomatic Pulmonary Arterial Hypertension Associated with Sickle Cell Disease.
Principal Investigator: Kamal Mubarak MD
ASSET-3: Long-Term, Open-Label, Multi-center, Extension Study of Bosentan in Patients with Pulmonary Hypertension Associated with Sickle Cell Disease Completing a Double-blind ASSET study.
Principal Investigator: Kamal Mubarak MD
PHIRST-1: Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients With Pulmonary Arterial Hypertension.
Principal Investigator: Kamal Mubarak MD